Nasdaq · Common Stock · Biological Products, (No Diagnostic Substances)
18 entities across 5 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-03-30 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| BRI-Alzan, Inc. | Delaware | |
| MeiraGTx B.V. | Netherlands | |
| MeiraGTx Netherlands B.V. | Netherlands | |
| MeiraGTx Limited | England and Wales | |
| MeiraGTx, LLC | Delaware | |
| MeiraGTx UK Limited | England and Wales | |
| MeiraGTx UK II Limited | England and Wales | |
| MeiraGTx Ireland DAC | Ireland | |
| MeiraGTx Neurosciences, Inc. | Delaware | |
| MeiraGTx Bio Inc. | Delaware | |
| MeiraGTx Belgium | Belgium | |
| MeiraGTx Therapeutics, Inc. | Delaware | |
| MeiraGTx Neuro I, LLC | Delaware | |
| MeiraGTx Neuro II, LLC | Delaware | |
| MeiraGTx Manufacturing Limited | England and Wales | |
| MeiraGTx Ocular UK Limited | England and Wales | |
| MeiraGTx Gene Regulation Limited | England and Wales | |
| MeiraGTx Neuro UK Limited | England and Wales |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $15.6M | −$58.0M | −$84.9M | — | 37,724,189 |
| FY2021 | $37.7M | −$79.6M | −$56.9M | — | 44,139,655 |
| FY2022 | $15.9M | −$129.6M | −$118.1M | — | 45,177,857 |
| FY2023 | $14.0M | −$84.0M | −$125.5M | — | 56,486,525 |
| FY2024 | $33.3M | −$147.8M | −$109.5M | — | 69,822,353 |
| FY2025 | $81.4M | −$114.2M | −$50.2M | — | 80,430,186 |
1 institutions tracked — 1 added, 0 reduced.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | Index | 849,082 | +264,183 | $11.5M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
MeiraGTx Holdings plc files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
